semaglutide tirzepatide weight loss mechanism and Medical Weight Loss — Shen

Description

The SCALE trial (2013) was the first document on how effective a GLP-1 (Liraglutide) can be when combined with lifestyle changes

12 The impact of these additional five years due to PTA and PTE is profound: Novo Nordisk is projected to earn an estimated $166 billion from Ozempic and Wegovy as a result of this extended period of patent protection, which spans from March 2026 to December 2031

Important Safety Information: Gastrointestinal Effects are the predominant side effects according to the prescribing information: Nausea (12-24% of patients) typically mild to moderate and often diminishes over time Diarrhea (13-17% of patients) usually transient and manageable with dietary modifications Vomiting (6-10% of patients) more common at higher doses Constipation (5-11% of patients) may require increased fluid intake and fiber Abdominal pain and dyspepsia (5-10% of patients) generally self-limiting Decreased appetite an expected pharmacological effect that contributes to weight loss These gastrointestinal symptoms are dose-dependent and typically most pronounced during the first few weeks after starting treatment or increasing the dose

And in the MCAS case series, most patients who stopped their GLP-1RA (whether due to cost, unavailability, or curiosity about what would happen) experienced a return of the symptoms that had been controlled